SCHEMBL21608045

SCHEMBL21608045

CC(=O)Nc1cc(CO)nn1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.41
MAPK14 Q16539 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
ALDH1A1 P00352 2/20 0.38
ADCY8 P40145 1/20 0.37
MAP4K4 O95819 1/20 0.37
ABL1 P00519 1/20 0.37
MAPK8 P45983 1/20 0.37
CSNK1A1 P48729 1/20 0.37
CDK7 P50613 1/20 0.37
TYRO3 Q06418 1/20 0.37
LRRK2 Q5S007 1/20 0.37
AURKB Q96GD4 1/20 0.37
CLK4 Q9HAZ1 1/20 0.37
PIM2 Q9P1W9 1/20 0.37
DYRK1B Q9Y463 1/20 0.37
PIK3CG P48736 1/20 0.36
MAPT P10636 5/20 0.35
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6564355 0.79 SMN1; SMN2 (0.37) SMN1; SMN2ALDH1A1MAPTPOLB
SCHEMBL15243733 0.77 SMN1; SMN2 (0.33) SMN1; SMN2MAPTPOLB
SCHEMBL48934 0.76 SMN1; SMN2 (0.68) SMN1; SMN2L3MBTL1ALDH1A1ADCY8PIK3CG
SCHEMBL8508457 0.72 GRN (0.55) ALDH1A1HSD17B10POLBKDM4E
SCHEMBL21608049 0.71 SMN1; SMN2 (0.41) SMN1; SMN2MAPK14L3MBTL1ALDH1A1MAP4K4
SCHEMBL7112019 0.71 MAPK14 (0.63) MAPK14MAPTLMNAKDM4E
SCHEMBL21607927 0.70 SMN1; SMN2 (0.40) SMN1; SMN2MAPK14L3MBTL1ALDH1A1PIK3CG
SCHEMBL20521432 0.70 CA12 (0.43) SMN1; SMN2L3MBTL1ALDH1A1MAPTHSD17B10
SCHEMBL14487008 0.70 BAZ2B (0.45) SMN1; SMN2L3MBTL1MAPK8MEN1KMT2A
SCHEMBL13170034 0.70 MAPK14 (0.48) SMN1; SMN2MAPK14ALDH1A1MAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210300900-A1 OGA INHIBITOR COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2021-09-30 US disclosed
WO-2019243531-A1 OGA INHIBITOR COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2019-12-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210300900-A1 OGA INHIBITOR COMPOUNDS OGA, OGT, GRN SMN1; SMN2 103/4885MAPK14 4406/4885L3MBTL1 1044/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.